Legend Biotech Corp (LEGN) Stock: What Does the Chart Say Thursday?

Legend Biotech Corp (LEGN) stock has fallen 4.79% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Legend Biotech Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LEGN!

See Full LEGN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With LEGN Stock Today?

Legend Biotech Corp (LEGN) stock is trading at $38.55 as of 4:00 PM on Thursday, Feb 17, a decline of -$3.05, or -7.33% from the previous closing price of $41.60. The stock has traded between $38.52 and $41.88 so far today. Volume today is light. So far 372,275 shares have traded compared to average volume of 597,425 shares. To see InvestorsObserver's Sentiment Score for Legend Biotech Corp click here.

More About Legend Biotech Corp

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America. Click Here to get the full Stock Report for Legend Biotech Corp stock.